Shots:

• The companies collaborate to develop and commercialize BPN14770 for AD- Fragile X syndrome and other indications marked by cognitive and memory deficits. Shionogi has increased its equity investment in Tetra to 50% and has an option to acquire the remaining equity if certain conditions are met based on the results of P-II PICASSO AD study assessing BPN14770 in patients with early AD
• In 2018- the companies collaborated for BPN14770- under which Shionogi got rights for the therapy in Japan- Taiwan and Korea while Tetra has received $40M as upfront including equity investment and licensing payment along with $120M as milestones & royalties on sales of the therapy
• BPN14770 is a novel therapy targeting PDE4D to enhance memory formation in children and older adults and has received the FDA’s ODD to treat Fragile X syndrome. Tetra is evaluating the therapy in P-II PICASSO AD study and an investigational P-II study in patients with AD & Fragile X syndrome respectively

Click here ­to­ read full press release/ article | Ref: Tetra Therapeutics | Image: Shionogi